Quick Answer
RetinalGenix Technologies Inc. reported Cash and Equivalents of $38.00 for fiscal year 2022.
RetinalGenix Technologies Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $38.00 | -99.2% |
| 2021 | $4.9K | +122.9% |
| 2020 | $2.2K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $44.00 | -98.8% | -97.7% |
| June 30, 2023 | $1.9K | +6985.2% | -74.4% |
| March 31, 2023 | $7.5K | — | +19557.9% |
| December 31, 2022 | $38.00 | -99.2% | -99.0% |
| September 30, 2022 | $3.6K | -90.1% | +13351.9% |
| June 30, 2022 | $27.00 | — | -99.5% |
| December 31, 2021 | $4.9K | +122.9% | -86.5% |
| September 30, 2021 | $36.6K | +21.6% | +1548.4% |
- RetinalGenix Technologies Inc. showed a decrease of -99.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2022 period, RetinalGenix Technologies Inc.’s cash and equivalents has declined by 98.3% (from $2.2 thousand to $38.00).
- The most recent figure is from RetinalGenix Technologies Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on April 1, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: